CSL Behring
🇧🇪Belgium
Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia
Phase 2
Completed
- Conditions
- NSCLCFatigueCachexia
- Interventions
- Biological: ALD518Biological: Infusion of 0.9% Saline without ALD518
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 124
- Registration Number
- NCT00866970
- Locations
- 🇮🇳
Mahavir Cancer Sansthan, Patna, India
🇷🇴Professor Dr. I Chiricuta Institute of Oncology and Radiotherapy, Cluj-Napoca, Romania
🇷🇺Territorial Clinical Oncology Dispensary, Krasnodar, Krasnodar Territory, Russian Federation
An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure
Phase 3
Completed
- Conditions
- Reversal of Coagulopathy
- Interventions
- Biological: Beriplex® P/N (Kcentra)Biological: Fresh frozen plasma
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2015-04-06
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 176
- Registration Number
- NCT00803101
- Locations
- 🇷🇺
Study Site, Saint Petersburg, Russian Federation
🇺🇸Study site, Bryan, Texas, United States
🇧🇬Study Site 4, Sofia, Bulgaria
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)
Phase 3
Completed
- Conditions
- Primary Immunodeficiency (PID)
- Interventions
- Biological: IgPro20
- First Posted Date
- 2008-09-12
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 40
- Registration Number
- NCT00751621
- Locations
- 🇬🇧
Study Site, London, United Kingdom
Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)
Phase 3
Completed
- Conditions
- Primary Immune Deficiency
- Interventions
- Biological: IgPro20
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 21
- Registration Number
- NCT00719680
- Locations
- 🇺🇸
Contact CSL Behring for facility details, Dallas, Texas, United States
Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy
Phase 3
Completed
- Conditions
- Blood Coagulation DisordersAcute Major Bleeding
- Interventions
- Biological: Fresh frozen plasmaBiological: Beriplex® P/N (Kcentra)
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 216
- Registration Number
- NCT00708435
- Locations
- 🇺🇦
Study Site, Vinnytsa, Ukraine
🇷🇺Study Site 1, St. Petersburg, Russian Federation
🇧🇬Study Site 4, Sofia, Bulgaria
A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)
Phase 2
Completed
- Conditions
- Multifocal Motor Neuropathy (MMN)
- Interventions
- Biological: Vivaglobin
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 8
- Registration Number
- NCT00701662
- Locations
- 🇨🇭
Inselspital, Bern, Switzerland
🇮🇹San Raffaele Hospital, Milan, Italy
🇬🇧Dept. Clinical Immunology, Oxford Radcliffe Hospitals, Oxford, United Kingdom
Haemocomplettan® P During Aortic Replacement
Phase 2
Completed
- Conditions
- Aortic Aneurysm
- Interventions
- Biological: Saline solutionBiological: Haemocomplettan® P
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 80
- Registration Number
- NCT00701142
- Locations
- 🇩🇪
Medical School Hannover (MHH), Hannover, Germany
A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)
Completed
- Conditions
- Von Willebrand Disease
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 21
- Registration Number
- NCT00701545
Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.
Phase 4
Completed
- Conditions
- Alpha 1-proteinase Inhibitor DeficiencyEmphysema
- Interventions
- Biological: Alpha1- proteinase inhibitor [human]
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 140
- Registration Number
- NCT00670007
- Locations
- 🇸🇪
Study Site, Malmo, Sweden
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy
Phase 3
Completed
- Conditions
- Autosomal Recessive AgammaglobulinemiaCommon Variable ImmunodeficiencyX-linked Agammaglobulinemia
- Interventions
- Biological: Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2011-09-01
- Lead Sponsor
- CSL Behring
- Target Recruit Count
- 51
- Registration Number
- NCT00542997
- Locations
- 🇬🇧
Study site, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath